TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) are effective cancer therapies.
• Targeting T cell malignancies with ADCs is challenging due to the need to spare normal T cells.
• T cells express either TRBC1 or TRBC2, with malignancies showing clonal expression of one allele.

Purpose of the Study:

• To develop a targeted therapy for T cell cancers expressing the TRBC2 allele.
• To create a high-affinity antibody specific for TRBC2.

Main Methods:

• Development of a high-affinity anti-TRBC2 antibody.
• Generation of an ADC using the anti-TRBC2 antibody and a pyrrolobenzodiazepine dimer payload.
• In vitro and in vivo testing in mouse models of TRBC2+ cancers.

Main Results:

• The anti-TRBC2 ADC demonstrated specific killing of TRBC2+ cancer cells.
• The ADC was effective in both in vitro and mouse model studies.
• Selective targeting preserves a significant population of normal T cells.

Conclusions:

• The developed anti-TRBC2 ADC is a promising therapeutic strategy for TRBC2+ T cell cancers.
• This ADC offers a potential off-the-shelf treatment option.
• Selective targeting of TRBC2 provides a method to spare normal T cells during cancer treatment.